IMFINZI plus tarlatamab interim DeLLphi-305 data show OS and PFS gains
Planned interim analysis of DeLLphi-305 Phase III showed IMFINZI (durvalumab) plus tarlatamab delivered statistically significant improvement in overall survival versus IMFINZI alone in 1st-line extensive-stage small cell lung cancer, with progression-free survival also improved.
Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) versus IMFINZI alone as a 1st-line maint…